Y-Intercept (HK)’s Collegium Pharmaceutical COLL Stock Holding History

Y-Intercept (HK)’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,748	Closed	-$686K	–	1780
2026 Q1	$686K	Buy	+20,748	New	+$878K	0.01%	1172

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Y-Intercept (HK)'s COLL Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Collegium Pharmaceutical (COLL) in Q2 2026, closing a stake of 20,748 shares — an estimated $686K sold.

Y-Intercept (HK) first reported a position in COLL in Q1 2026 and held it in 1 quarter. The position peaked at $686K in Q1 2026. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Y-Intercept (HK) reported no remaining Collegium Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 20,748 Collegium Pharmaceutical shares in Q2 2026, an estimated $686K.
Y-Intercept (HK) first reported a position in Collegium Pharmaceutical in Q1 2026 and held it in 1 quarter.
Y-Intercept (HK)'s Collegium Pharmaceutical position peaked at $686K in Q1 2026.
280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.